Clinical trials: Blood Loss
Epistaxis
NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial
The purpose of this research study is to determine whether Doxycycline can be used to control nosebleeds (epistaxis) for patients with Hereditary Hemorrhagic Telangiectasia (HHT).
- Trial name
- NOSTRIL (NCT04167085)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, Los Angeles
Sleep Apnea, Obstructive
Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy
Hemostasis will be achieved during Pediatric Tonsillectomy/Adenoidectomy with the use of QuickClot.
- Trial name
- NCT01863563
- Testing
- QuickClot
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eastern Virginia Medical School
Blood Loss During Vaginal Hysterectomy
Comparison of the Effects of Cervical Vasopressin Versus no Premedication on Blood Loss During Vaginal Hysterectomy: A Randomized, Placebo Controlled Trial
Vasoconstrictive agents are increasingly being used in order to decrease blood loss during vaginal hysterectomy. The first reported study of the use of a vasoconstrictive agent for this purpose was on the use of epinephrine…
- Trial name
- NCT00799292
- Testing
- Vasopressin
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Ascher-Walsh, Charles, M.D.
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
- Trial name
- NCT03338998
- Testing
- BAF312 solution, BAF312 tablet
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Immune Thrombocytopenic Purpura
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).
- Trial name
- FIT (NCT02076399)
- Testing
- Fostamatinib disodium
- Where
- 52 sites in United States, Australia and 6 more
- Volunteers
- 76 people
- Sponsor
- Rigel Pharmaceuticals
Congenital Bleeding Disorder, Haemophilia A
Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
This trial is conducted in China. The aim of this trial is to evaluate the clinical efficacy of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe haemophilia A (FVIII≤1%).
- Trial name
- guardian TM 7 (NCT02938585)
- Testing
- turoctocog alfa
- Where
- 11 sites in China
- Volunteers
- 68 people
- Sponsor
- Novo Nordisk A/S
Von Willebrand Diseases
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
The purpose of this study is to prospectively obtain reliable data on the bleeding and treatment pattern of patients with VWD undergoing on-demand treatment with a VWF-containing product over a period of 6 months.
- Trial name
- NCT04053699
- Testing
- Von Willebrand Factor-Containing Product
- Where
- 15 sites in United States, Belarus and 6 more
- Volunteers
- 56 people
- Sponsor
- Octapharma
Non ST Segment Elevation Acute Coronary Syndrome
Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI
It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.
- Trial name
- NCT01962428
- Testing
- ticagrelor
- Where
- 2 sites in China
- Volunteers
- 250 people
- Sponsor
- General Hospital of Chinese Armed Police Forces
Subarachnoid Hemorrhage, Stroke
Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH
This study compares the bioavailability of IV and PO acetaminophen in both blood and the cerebrospinal fluid (CSF) of patients following subarachnoid hemorrhage.
- Trial name
- aSAH (NCT02549716)
- Testing
- IV acetaminophen, Oral acetaminophen
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Milton S. Hershey Medical Center
Peripheral Arterial Hemorrhage
Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
To evaluate the safety and effectiveness of the Lava LES for the embolic treatment of arterial hemorrhage in the peripheral vasculature.
- Trial name
- NCT04649255
- Testing
- Liquid Embolic
- Where
- 9 sites in United States
- Volunteers
- 113 people
- Sponsor
- BlackSwan Vascular, Inc.
Endoleaks
Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair
This study will be a cross-sectional survey of interobserver variability associated with contrast enhanced ultrasound (CEUS) to detect endoleaks using computed tomographic angiography (CTA) as the practice standard.
- Trial name
- AAA CEUS (NCT01005212)
- Testing
- Definity
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- E. Peden, MD
Intracerebral Hemorrhage
High-Dose Deferoxamine in Intracerebral Hemorrhage
The main purpose of this study is to determine whether treatment with deferoxamine mesylate is of sufficient promise to improve outcome before pursuing a larger clinical trial to examine its effectiveness as a treatment for brain…
- Trial name
- HI-DEF (NCT01662895)
- Testing
- Deferoxamine, Normal saline
- Where
- 29 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- Beth Israel Deaconess Medical Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
This phase II MATCH treatment trial identifies the effects of VS-6063 (defactinib) in patients whose cancer has a genetic change called NF2 mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439331
- Testing
- Defactinib Hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Congenital Bleeding Disorder, Haemophilia A
Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
This trial is conducted in Asia, Europe, and North and South America. The aim of this clinical trial is to investigate the safety and efficacy of turoctocog alfa (recombinant factor VIII, rFVIII (N8)) in male previously treated…
- Trial name
- guardian™ 3 (NCT01138501)
- Testing
- turoctocog alfa
- Where
- 38 sites in United States, Brazil and 11 more
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Intracerebral Hemorrhage, Cerebral Edema
Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
The purpose of this study is to test the safety and effectiveness of a single dose of fingolimod in patients with primary spontaneous intracerebral hemorrhage (ICH).
- Conditions
- Intracerebral Hemorrhage, Cerebral Edema, Stroke Hemorrhagic, Intracerebral Hemorrhage, Hypertensive
- Trial name
- FITCH (NCT04088630)
- Testing
- Fingolimod, Open-label Fingolimod
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Wake Forest University Health Sciences
Venous Thromboembolism
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study
This vanguard pilot study compares rivaroxaban and apixaban, two of the new oral blood thinners for the treatment of blood clots. Half of the patients will receive apixaban and half will receive rivaroxaban.
- Trial name
- COBRRA Pilot (NCT02559856)
- Testing
- Apixaban, Rivaroxaban
- Where
- 4 sites in Canada
- Volunteers
- 71 people
- Sponsor
- Ottawa Hospital Research Institute
Hemorrhagic Shock
Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
Based on encouraging results from animal studies, the investigators hypothesize that early administration of IV Premarin® in patients with hemorrhagic shock will safely reduce secondary injury, and improve survival.
- Trial name
- RESCUE-Shock (NCT00973102)
- Testing
- Premarin IV
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Texas Southwestern Medical Center
Idiopathic Thrombocytopenic Purpura
IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic (immune) thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by platelet destruction and thrombocytopenia (peripheral blood platelet count < 150 x 10^9/L).
- Trial name
- NCT00511147
- Testing
- IGIV3I Grifols 10%
- Where
- 45 sites in United States, Canada and 2 more
- Volunteers
- 64 people
- Sponsor
- Grifols Biologicals, LLC
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
PROPACT: Retrospective Prophylaxis Patient Case Collection
This study is conducted in Europe and North and South America. The primary aim of this observational study is to evaluate the frequency and pattern of bleeding episodes in haemophilia patients receiving preventative treatment…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- PROPACT (NCT00882778)
- Testing
- eptacog alfa (activated)
- Where
- 14 sites in United States, Argentina and 12 more
- Volunteers
- 86 people
- Sponsor
- Novo Nordisk A/S
Subarachnoid Hemorrhage
Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa
This is a prospective, randomized, double-blinded, placebo controlled pilot safety study that will enroll a total of twenty subjects.
- Trial name
- EPO (NCT00626574)
- Testing
- Epoetin alfa, Saline
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of South Florida